Ligand bias prevents class equality among beta-blockers

Current Opinion in Pharmacology

Volumn 16, Issue 1, 2014, Pages 50-57

  Thanawala, Vaidehi J ^a   Forkuo, Gloria S ^a   Stallaert, Wayne ^b,c   Leff, Paul ^d   Bouvier, Michel ^b,c   Bond, Richard ^a  

^a UNIVERSITY OF HOUSTON   (United States)

^b UNIVERSITÉ DE MONTRÉAL   (Canada)

^c INSTITUTE FOR RESEARCH IN IMMUNOLOGY AND CANCER   (Canada)

^d NONE   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

BETA ADRENERGIC RECEPTOR BLOCKING AGENT; G PROTEIN COUPLED RECEPTOR; BETA 2 ADRENERGIC RECEPTOR; LIGAND;

ARTICLE; ASTHMA; BINDING AFFINITY; BRONCHUS HYPERREACTIVITY; CONGESTIVE HEART FAILURE; DRUG APPROVAL; DRUG CHOICE; DRUG CLASSIFICATION; DRUG EFFICACY; DRUG INDICATION; DRUG MECHANISM; DRUG RECEPTOR BINDING; DRUG SELECTIVITY; GLAUCOMA; HEART FAILURE; HIGH THROUGHPUT SCREENING; HUMAN; HYPERTENSION; LIGAND BINDING; NONHUMAN; PATHOPHYSIOLOGY; PRIORITY JOURNAL; PROTEIN CONFORMATION; SIGNAL TRANSDUCTION; ANIMAL; CLASSIFICATION; METABOLISM;

ADRENERGIC BETA-ANTAGONISTS; ANIMALS; ASTHMA; HUMANS; LIGANDS; RECEPTORS, ADRENERGIC, BETA-2; SIGNAL TRANSDUCTION;

EID: 84897428329     PISSN: 14714892     EISSN: 14714973     Source Type: Journal    
DOI: 10.1016/j.coph.2014.03.002     Document Type: Review

References (53)

1. P.J. Barnes Drugs for asthma Br J Pharmacol 147 Suppl 1 2006 S297 S303 (Pubitemid 43077288)
2. C.J. Cates, and M.J. Cates Regular treatment with formoterol for chronic asthma: serious adverse events Cochrane Database Syst Rev 4 2012 CD006923
3. H.S. Nelson, S.T. Weiss, E.R. Bleecker, S.W. Yancey, and P.M. Dorinsky The Salmeterol Multicenter Asthma Research Trial: a comparison of usual pharmacotherapy for asthma or usual pharmacotherapy plus salmeterol Chest 129 2006 15 26 (Pubitemid 43265239)
4. R. Lin, S. Degan, B.S. Theriot, B.M. Fischer, R.T. Strachan, J. Liang, R.A. Pierce, M.E. Sunday, P.W. Noble, and M. Kraft et al. Chronic treatment in vivo with beta-adrenoceptor agonists induces dysfunction of airway beta(2)-adrenoceptors and exacerbates lung inflammation in mice Br J Pharmacol 165 2012 2365 2377
5. L.P. Nguyen, R. Lin, S. Parra, O. Omoluabi, N.A. Hanania, M.J. Tuvim, B.J. Knoll, B.F. Dickey, and R.A. Bond Beta2-adrenoceptor signaling is required for the development of an asthma phenotype in a murine model Proc Natl Acad Sci U S A 106 2009 2435 2440
6. L.P. Nguyen, O. Omoluabi, S. Parra, J.M. Frieske, C. Clement, Z. Ammar-Aouchiche, S.B. Ho, C. Ehre, M. Kesimer, and B.J. Knoll et al. Chronic exposure to beta-blockers attenuates inflammation and mucin content in a murine asthma model Am J Respir Cell Mol Biol 38 2008 256 262 (Pubitemid 351567693)
7. Z. Callaerts-Vegh, K.L. Evans, N. Dudekula, D. Cuba, B.J. Knoll, P.F. Callaerts, H. Giles, F.R. Shardonofsky, and R.A. Bond Effects of acute and chronic administration of beta-adrenoceptor ligands on airway function in a murine model of asthma Proc Natl Acad Sci U S A 101 2004 4948 4953 (Pubitemid 38469183)
8. T. Costa, and A. Herz Antagonists with negative intrinsic activity at delta opioid receptors coupled to GTP-binding proteins Proc Natl Acad Sci U S A 86 1989 7321 7325 (Pubitemid 19254452)
9. P. Chidiac, T.E. Hebert, M. Valiquette, M. Dennis, and M. Bouvier Inverse agonist activity of beta-adrenergic antagonists Mol Pharmacol 45 1994 490 499 (Pubitemid 24094939)
10. A. De Lean, J.M. Stadel, and R.J. Lefkowitz A ternary complex model explains the agonist-specific binding properties of the adenylate cyclase-coupled beta-adrenergic receptor J Biol Chem 255 1980 7108 7117 (Pubitemid 11232874)
11. R.J. Lefkowitz, S. Cotecchia, P. Samama, and T. Costa Constitutive activity of receptors coupled to guanine nucleotide regulatory proteins Trends Pharmacol Sci 14 1993 303 307 (Pubitemid 23242583)
12. J. Monod, J. Wyman, and J.P. Changeux On the nature of allosteric transitions: a plausible model J Mol Biol 12 1965 88 118
13. P. Samama, S. Cotecchia, T. Costa, and R.J. Lefkowitz A mutation-induced activated state of the beta 2-adrenergic receptor. Extending the ternary complex model J Biol Chem 268 1993 4625 4636 (Pubitemid 23081571)
14. E.L. Barker, R.S. Westphal, D. Schmidt, and E. Sanders-Bush Constitutively active 5-hydroxytryptamine2C receptors reveal novel inverse agonist activity of receptor ligands J Biol Chem 269 1994 11687 11690
15. R.A. Bond, P. Leff, T.D. Johnson, C.A. Milano, H.A. Rockman, T.R. McMinn, S. Apparsundaram, M.F. Hyek, T.P. Kenakin, and L.F. Allen et al. Physiological effects of inverse agonists in transgenic mice with myocardial overexpression of the beta 2-adrenoceptor Nature 374 1995 272 276
16. P. Leff The two-state model of receptor activation Trends Pharmacol Sci 16 1995 89 97
17. V.J. Thanawala, G.S. Forkuo, N. Al-Sawalha, Z. Azzegagh, L.P. Nguyen, J.L. Eriksen, M.J. Tuvim, T.W. Lowder, B.F. Dickey, and B.J. Knoll et al. beta2-Adrenoceptor agonists are required for development of the asthma phenotype in a murine model Am J Respir Cell Mol Biol 48 2013 220 229
18. N.A. Hanania, S. Singh, R. El-Wali, M. Flashner, A.E. Franklin, W.J. Garner, B.F. Dickey, S. Parra, S. Ruoss, and F. Shardonofsky et al. The safety and effects of the beta-blocker, nadolol, in mild asthma: an open-label pilot study Pulm Pharmacol Ther 21 2008 134 141
19. N.A. Hanania, B. Mannava, A.E. Franklin, B.J. Lipworth, P.A. Williamson, W.J. Garner, B.F. Dickey, and R.A. Bond Response to salbutamol in patients with mild asthma treated with nadolol Eur Respir J 36 2010 963 965
20. P.M. Short, P.A. Williamson, W.J. Anderson, and B.J. Lipworth Randomized placebo-controlled trial to evaluate chronic dosing effects of propranolol in asthma Am J Respir Crit Care Med 187 2013 1308 1314
21. S. Kazani, and E. Israel What doesn't kill may not make you stronger. beta-Blockers for asthma Am J Respir Crit Care Med 187 2013 1281
22. T. Gudermann, F. Kalkbrenner, and G. Schultz Diversity and selectivity of receptor-G protein interaction Annu Rev Pharmacol 36 1996 429 459 (Pubitemid 26168705)
23. T. Kenakin Agonist-receptor efficacy. II. Agonist trafficking of receptor signals Trends Pharmacol Sci 16 1995 232 238
24. K.A. Berg, S. Maayani, J. Goldfarb, C. Scaramellini, P. Leff, and W.P. Clarke Effector pathway-dependent relative efficacy at serotonin type 2A and 2C receptors: evidence for agonist-directed trafficking of receptor stimulus Mol Pharmacol 54 1998 94 104 (Pubitemid 28337591)
25. E. Reiter, S. Ahn, A.K. Shukla, and R.J. Lefkowitz Molecular mechanism of beta-arrestin-biased agonism at seven-transmembrane receptors Annu Rev Pharmacol 52 2012 179 197
26. S.K. Shenoy, M.T. Drake, C.D. Nelson, D.A. Houtz, K. Xiao, S. Madabushi, E. Reiter, R.T. Premont, O. Lichtarge, and R.J. Lefkowitz beta-Arrestin- dependent, G protein-independent ERK1/2 activation by the beta2 adrenergic receptor J Biol Chem 281 2006 1261 1273
27. J.W. Wisler, S.M. DeWire, E.J. Whalen, J.D. Violin, M.T. Drake, S. Ahn, S.K. Shenoy, and R.J. Lefkowitz A unique mechanism of beta-blocker action: carvedilol stimulates beta-arrestin signaling Proc Natl Acad Sci U S A 104 2007 16657 16662 (Pubitemid 350211072)
28. S. Rajagopal, S. Ahn, D.H. Rominger, W. Gowen-MacDonald, C.M. Lam, S.M. Dewire, J.D. Violin, and R.J. Lefkowitz Quantifying ligand bias at seven-transmembrane receptors Mol Pharmacol 80 2011 367 377
29. S. Galandrin, and M. Bouvier Distinct signaling profiles of beta1 and beta2 adrenergic receptor ligands toward adenylyl cyclase and mitogen-activated protein kinase reveals the pluridimensionality of efficacy Mol Pharmacol 70 2006 1575 1584
30. M. Azzi, P.G. Charest, S. Angers, G. Rousseau, T. Kohout, M. Bouvier, and G. Pineyro Beta-arrestin-mediated activation of MAPK by inverse agonists reveals distinct active conformations for G protein-coupled receptors Proc Natl Acad Sci U S A 100 2003 11406 11411 (Pubitemid 37205948)
31. S. Galandrin, G. Oligny-Longpre, and M. Bouvier The evasive nature of drug efficacy: implications for drug discovery Trends Pharmacol Sci 28 2007 423 430 (Pubitemid 47087968)
32. P. Leff, C. Scaramellini, C. Law, and K. McKechnie A three-state receptor model of agonist action Trends Pharmacol Sci 18 1997 355 362 (Pubitemid 27435058)
33. D.P. Staus, L.M. Wingler, R.T. Strachan, S.G. Rasmussen, E. Pardon, S. Ahn, J. Steyaert, B.K. Kobilka, and R.J. Lefkowitz Regulation of beta2-adrenergic receptor function by conformationally selective single-domain intrabodies Mol Pharmacol 85 2014 472 481
34. E.T. van der Westhuizen, B. Breton, A. Christopoulos, and M. Bouvier Quantification of ligand bias for clinically relevant beta2-adrenergic receptor ligands: implications for drug taxonomy Mol Pharmacol 85 2014 492 509
35. Effect of metoprolol CR/XL in chronic heart failure: metoprolol CR/XL Randomised Intervention Trial in Congestive Heart Failure (MERIT-HF) Lancet 353 1999 2001 2007
36. A. Hjalmarson, S. Goldstein, B. Fagerberg, H. Wedel, F. Waagstein, J. Kjekshus, J. Wikstrand, D. El Allaf, J. Vitovec, and J. Aldershvile et al. Effects of controlled-release metoprolol on total mortality, hospitalizations, and well-being in patients with heart failure: the Metoprolol CR/XL Randomized Intervention Trial in congestive heart failure (MERIT-HF). MERIT-HF StuGroup JAMA 283 2000 1295 1302 (Pubitemid 30129796)
37. The Cardiac Insufficiency Bisoprolol Study II (CIBIS-II): a randomised trial Lancet 353 1999 9 13
38. M. Packer, M.R. Bristow, J.N. Cohn, W.S. Colucci, M.B. Fowler, E.M. Gilbert, and N.H. Shusterman The effect of carvedilol on morbidity and mortality in patients with chronic heart failure. U. S. Carvedilol Heart Failure Study Group N Engl J Med 334 1996 1349 1355 (Pubitemid 26152713)
39. A trial of the beta-blocker bucindolol in patients with advanced chronic heart failure N Engl J Med 344 2001 1659 1667
40. B.A. Mulder, D.J. van Veldhuisen, H.J. Crijns, M. Bohm, A. Cohen-Solal, D. Babalis, M. Roughton, M.D. Flather, A.J. Coats, and I.C. Van Gelder Effect of nebivolol on outcome in elderly patients with heart failure and atrial fibrillation: insights from SENIORS Eur J Heart Failure 14 2012 1171 1178
41. D.J. van Veldhuisen, A. Cohen-Solal, M. Bohm, S.D. Anker, D. Babalis, M. Roughton, A.J. Coats, P.A. Poole-Wilson, and M.D. Flather Beta-blockade with nebivolol in elderly heart failure patients with impaired and preserved left ventricular ejection fraction: Data From SENIORS (Study of Effects of Nebivolol Intervention on Outcomes and Rehospitalization in Seniors With Heart Failure) J Am Coll Cardiol 53 2009 2150 2158
42. S. Witchitz, A. Cohen-Solal, N. Dartois, N. Weisslinger, K. Juste, and J.Y. Darmon Treatment of heart failure with celiprolol, a cardioselective beta blocker with beta-2 agonist vasodilatory properties. The CELICARD Group Am J Cardiol 85 2000 1467 1471 (Pubitemid 30336584)
43. R.A. Bond The intrinsic bias of generalizations Am J Respir Crit Care Med 189 2014 359
44. B. Lipworth, P. Short, W. Anderson, and P. Williamson Reply: pharmacological obfuscation of clinical relevance Am J Respir Crit Care Med 189 2014 360 361
45. R.B. Penn Far from "disappointing" Am J Respir Crit Care Med 189 2014 360
46. J.K. Walker, R.B. Penn, N.A. Hanania, B.F. Dickey, and R.A. Bond New perspectives regarding beta(2)-adrenoceptor ligands in the treatment of asthma Br J Pharmacol 163 2011 18 28
47. J.K. Walker, A.M. Fong, B.L. Lawson, J.D. Savov, D.D. Patel, D.A. Schwartz, and R.J. Lefkowitz Beta-arrestin-2 regulates the development of allergic asthma J Clin Investig 112 2003 566 574 (Pubitemid 38056341)
48. M.T. Drake, J.D. Violin, E.J. Whalen, J.W. Wisler, S.K. Shenoy, and R.J. Lefkowitz beta-Arrestin-biased agonism at the beta2-adrenergic receptor J Biol Chem 283 2008 5669 5676
49. W. Stallaert, J.F. Dorn, E. van der Westhuizen, M. Audet, and M. Bouvier Impedance responses reveal beta(2)-adrenergic receptor signaling pluridimensionality and allow classification of ligands with distinct signaling profiles PloS One 7 2012 e29420
50. R. Lin, H. Peng, L.P. Nguyen, N.B. Dudekula, F. Shardonofsky, B.J. Knoll, S. Parra, and R.A. Bond Changes in beta 2-adrenoceptor and other signaling proteins produced by chronic administration of 'beta-blockers' in a murine asthma model Pulm Pharmacol Ther 21 2008 115 124
51. E. van der Westhuizen, B. Breton, A. Christopoulos, and M. Bouvier Quantification of ligand bias for clinically relevant b2-adrenergic receptor ligands: implications for drug taxonomy Mol Pharmacol 85 2014 492 5091
52. P.M. Short, W.J. Anderson, P.A. Williamson, and B.J. Lipworth Effects of intravenous and oral beta-blockade in persistent asthmatics controlled on inhaled corticosteroids Heart 100 2014 219 223
53. Y. Daaka, L.M. Luttrell, and R.J. Lefkowitz Switching of the coupling of the beta2-adrenergic receptor to different G proteins by protein kinase A Nature 390 1997 88 91 (Pubitemid 27494762)